Abstract | OBJECTIVE:
Limitin is a new member of type I interferon (IFN) identified with an expression cloning based on the growth suppression of a myelomonocytic leukemia cell line WEHI3. Although limitin uses the IFN-alpha/beta receptor, its signal transduction pathways to express the antiviral effects are different from those of IFN-alpha. To clarify the characteristics of limitin, we compared the biological activities of limitin, such as the antiviral, immunomodulatory, antitumor, and myelosuppressive effects, with IFN-alpha. MATERIALS AND METHODS:
Limitin and IFN-alpha were titered with a cytopathic effect dye binding assay. Induction of MHC class I on a keratinocyte cell line PAM212 was estimated with flow cytometry. Induction of OVA-restricted cytotoxic T lymphocyte (CTL) activity was analyzed with 51Cr release assay. Antiproliferative effects were evaluated with 3H-thymidine incorporation assay using WEHI3 and a lymphoblast cell line L1210. Myelosuppresive effects were evaluated with colony assay. In vivo side effects were estimated after the injection of limitin or IFN-alpha. RESULTS:
Limitin had relatively higher antiviral activity than IFN-alpha. Limitin induced the surface expression of MHC class I, the enhancement of CTL activity, and the growth inhibition of lymphohematopoietic cell lines as strong as IFN-alpha. Nevertheless, the treatment of mice with limitin showed neither myelosuppression nor fever that are common adverse effects of IFN-alpha. CONCLUSIONS: Strong immunomodulatory, antitumor, and antiviral effects with weak myelosuppressive and weak acute toxic effects of limitin indicate that it may be useful as a new therapeutic drug for virus-hepatitis and cancers.
|
Authors | Shin-ichiro Kawamoto, Kenji Oritani, Eiji Asakura, Jun Ishikawa, Mamoru Koyama, Kenmi Miyano, Minori Iwamoto, Shin-ichiro Yasuda, Hirosi Nakakubo, Fumihiro Hirayama, Naoko Ishida, Hidetoshi Ujiie, Hiroaki Masaie, Yoshiaki Tomiyama |
Journal | Experimental hematology
(Exp Hematol)
Vol. 32
Issue 9
Pg. 797-805
(Sep 2004)
ISSN: 0301-472X [Print] Netherlands |
PMID | 15345280
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Antineoplastic Agents
- Cytokines
- Interferon-alpha
- limitin
|
Topics |
- Adjuvants, Immunologic
(pharmacology)
- Animals
- Antineoplastic Agents
(pharmacology)
- Bone Marrow
(drug effects)
- Cell Line
- Cytokines
(pharmacology, toxicity)
- Hematopoiesis
(drug effects)
- Interferon-alpha
(pharmacology, toxicity)
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
|